4.1.4.2.2.2 Summary of evidence and recommendation for Beta-3 agonists,
Summary of evidence,LE
Mirabegron and vibegron are better than placebo for improvement of OAB/UUI symptoms.,1a
Adverse event rates with mirabegron and vibegron are similar to those of placebo.,1a
Beta-3 agonists are as effective as antimuscarinics in the management of OAB but with lower dry   mouth rates.,1a
Patients inadequately treated with solifenacin 5 mg may benefit more from the addition of mirabegron   rather than dose escalation of solifenacin.,1b
Recommendations,Strength rating
Offer beta-3 agonists as an alternative to anticholinergics to women with OAB who fail   conservative treatment.,Strong
Offer mirabegron as an additional therapy in patients who are inadequately treated with   solifenacin 5 mg.,Weak
